Eleven compounds, [Zn(L1)2(bbmi)] (1), [Zn(HL2)2(bbmi)] (2), [Zn0.5(L3)(bbmi)0.5] (3), [Zn0.5(L4)(bbmi)0.5(H2O)] (4), [Zn(L5)2(bbmi)] (5), [Zn(L6)(bbmi)] (6), [Zn(L7)(bbmi)0.5(H2O)] (7), [Zn(L8)(bbmi)0.5(H2O)] (8), [Ag2(L6)(bbmi)(H2O)] (9), [Ag(L9)0.5(bbmi)0.5]·2H2O (10) and [Ag2.5(L10)(bbmi)2]·0.5(OH)·0.5(EtOH)·1.5H2O (11), where bbmi = 1,1′-(1,4-butanediyl)bis(2-methylbenzimidazole), HL1 = benzoic acid, H2L2 = salicylic acid, HL3 = p-nitrobenzoic acid, HL4 = nicotinic acid, HL5 = 3,5-dinitrobenzoic acid, H2L6 = o-phthalic acid, H2L7 = m-phthalic acid, H2L8 = fumaric acid, H2L9 = p-phthalic acid and H2L10 = 5-aminoisophthalic acid, have been synthesized and characterized. Compounds 1–5 and 10 display one-dimensional chain structures. These chains are connected through intermolecular interactions to form 2D supramolecular structures, respectively. The layers of 2 are further connected through C–H⋯π interactions to yield a 3D supramolecular structure. There exist weak Ag⋯Ag interactions in 10, which also contribute to the stabilization of the supramolecular layer. Compound 6 exhibits a diamondoid network. Compound 7 shows a 2D (4,4) layer. The structure of 8 is a 3D α-Po framework. Compound 9 displays a 2D layer structure. Furthermore, the π–π interactions among the bbmi ligands link the layers into a 3D supramolecular framework. Compound 11 shows a ladder structure. The Ag⋯Ag and π–π interactions further connect the ladders to form a 2D supramolecular assembly. The thermal stabilities of 4 and 7–11 and the luminescent properties of 1, 3–5 and 7–11 in the solid state are also discussed.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: